TrialInternational journal of clinical practice2017

Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE).

Marcus J Drake et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.